TNSN98123A1 - Formes posologiques de sertraline et procede pour leur preparation - Google Patents
Formes posologiques de sertraline et procede pour leur preparationInfo
- Publication number
- TNSN98123A1 TNSN98123A1 TNTNSN98123A TNSN98123A TNSN98123A1 TN SN98123 A1 TNSN98123 A1 TN SN98123A1 TN TNSN98123 A TNTNSN98123 A TN TNSN98123A TN SN98123 A TNSN98123 A TN SN98123A TN SN98123 A1 TNSN98123 A1 TN SN98123A1
- Authority
- TN
- Tunisia
- Prior art keywords
- dosage forms
- sertraline
- preparation
- reduced
- miscible
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract 3
- 229960002073 sertraline Drugs 0.000 title abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
L'INVENTION CONCERNE DES FORMES POSOLOGIQUES DE SERTRALINE. CES FORMES POSOLOGIQUES SONT ENCAPSULEES DANS UN VEHICULE NON MISCIBLE A L'EAU ET PRESENTANT UN Tmax REDUIT ET/OU DES EFFETS SECONDAIRES REDUITS ET/OU UNE DIMINUTION DE LA PRECIPITATION DE LA SERTRALINE DANS DES ENVIRONNEMENTS D'UTILISATION CONTENANT DES IONS CHLORURE TELS QUE LE TRACTUS GASTRO INTESTINAL. APPLICATION : UTILISATION DE CES FORMES POSOLOGIQUES POUR LE TRAITEMENT DE DIVERSES MALADIES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5140197P | 1997-07-01 | 1997-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN98123A1 true TNSN98123A1 (fr) | 2005-03-15 |
Family
ID=21971076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN98123A TNSN98123A1 (fr) | 1997-07-01 | 1998-06-30 | Formes posologiques de sertraline et procede pour leur preparation |
Country Status (40)
| Country | Link |
|---|---|
| EP (1) | EP0980241B1 (fr) |
| JP (1) | JP3585245B2 (fr) |
| KR (1) | KR100371730B1 (fr) |
| CN (1) | CN1261792A (fr) |
| AP (1) | AP945A (fr) |
| AR (1) | AR015916A1 (fr) |
| AT (1) | ATE256457T1 (fr) |
| AU (1) | AU724635B2 (fr) |
| BG (1) | BG103917A (fr) |
| BR (1) | BR9809712A (fr) |
| CA (1) | CA2290973C (fr) |
| CO (1) | CO4940405A1 (fr) |
| DE (1) | DE69820608T2 (fr) |
| DK (1) | DK0980241T3 (fr) |
| DZ (1) | DZ2544A1 (fr) |
| EA (1) | EA001905B1 (fr) |
| ES (1) | ES2210760T3 (fr) |
| GT (1) | GT199800090A (fr) |
| HR (1) | HRP980378B1 (fr) |
| HU (1) | HUP0002250A3 (fr) |
| ID (1) | ID24673A (fr) |
| IL (1) | IL133075A0 (fr) |
| IS (1) | IS5266A (fr) |
| MA (1) | MA24586A1 (fr) |
| MY (1) | MY119728A (fr) |
| NO (1) | NO996492L (fr) |
| NZ (1) | NZ501252A (fr) |
| OA (1) | OA11246A (fr) |
| PA (1) | PA8454001A1 (fr) |
| PE (1) | PE97299A1 (fr) |
| PL (1) | PL337807A1 (fr) |
| PT (1) | PT980241E (fr) |
| SK (1) | SK282914B6 (fr) |
| TN (1) | TNSN98123A1 (fr) |
| TR (1) | TR199903282T2 (fr) |
| TW (1) | TW382597B (fr) |
| UA (1) | UA68350C2 (fr) |
| UY (1) | UY25070A1 (fr) |
| WO (1) | WO1999001113A1 (fr) |
| ZA (1) | ZA985709B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA003990B1 (ru) * | 1998-10-13 | 2003-12-25 | Пфайзер Продактс Инк. | Пероральный концентрат сертралина |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| ATE318135T1 (de) | 1999-09-03 | 2006-03-15 | Apbi Holdings Llc | Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| EP1375659A1 (fr) * | 2002-06-18 | 2004-01-02 | Laboratorio di Diagnostica Moleculare | Mélanges concentrés dans des capsules solubles pour la préparation facilitée de solutions chimiques ou biologiques |
| JP2006507309A (ja) * | 2002-10-31 | 2006-03-02 | アルザ・コーポレーシヨン | 疎水性薬剤の上昇した生物学的利用性を提供する製剤 |
| WO2016020936A2 (fr) * | 2014-07-21 | 2016-02-11 | Patel Jayendrakumar Dasharathlal | Nouvelle forme posologique pharmaceutique orale de rétention gastrique |
| CN108014087A (zh) * | 2017-12-27 | 2018-05-11 | 江苏联环药业股份有限公司 | 一种盐酸舍曲林胶囊的制备方法 |
| GB2630572A (en) | 2023-05-29 | 2024-12-04 | Novumgen Ltd | An orally disintegrating tablet of sertraline and its process of preparation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0782445B1 (fr) * | 1994-09-19 | 2002-03-13 | Dupont Pharmaceuticals Company | Combinaison d'un antagoniste opioide et d'un inhibiteur selectif de recaptage de serotonine pour le traitement de l'alcoolisme et de l'alcoolodependance |
| ATE235237T1 (de) * | 1995-07-17 | 2003-04-15 | Pfizer | Sertralin zur behandlung von post-myocard-infarkt-patienten |
-
1998
- 1998-06-16 EA EA199900963A patent/EA001905B1/ru not_active IP Right Cessation
- 1998-06-16 NZ NZ501252A patent/NZ501252A/en unknown
- 1998-06-16 IL IL13307598A patent/IL133075A0/xx unknown
- 1998-06-16 DK DK98923021T patent/DK0980241T3/da active
- 1998-06-16 TR TR1999/03282T patent/TR199903282T2/xx unknown
- 1998-06-16 CN CN98806765A patent/CN1261792A/zh active Pending
- 1998-06-16 BR BR9809712-1A patent/BR9809712A/pt not_active Application Discontinuation
- 1998-06-16 AU AU75450/98A patent/AU724635B2/en not_active Ceased
- 1998-06-16 KR KR10-1999-7011596A patent/KR100371730B1/ko not_active Expired - Fee Related
- 1998-06-16 HU HU0002250A patent/HUP0002250A3/hu unknown
- 1998-06-16 UA UA99116393A patent/UA68350C2/uk unknown
- 1998-06-16 ES ES98923021T patent/ES2210760T3/es not_active Expired - Lifetime
- 1998-06-16 SK SK1805-99A patent/SK282914B6/sk unknown
- 1998-06-16 WO PCT/IB1998/000936 patent/WO1999001113A1/fr not_active Ceased
- 1998-06-16 EP EP98923021A patent/EP0980241B1/fr not_active Expired - Lifetime
- 1998-06-16 PT PT98923021T patent/PT980241E/pt unknown
- 1998-06-16 AT AT98923021T patent/ATE256457T1/de not_active IP Right Cessation
- 1998-06-16 CA CA002290973A patent/CA2290973C/fr not_active Expired - Fee Related
- 1998-06-16 PL PL98337807A patent/PL337807A1/xx unknown
- 1998-06-16 JP JP50677699A patent/JP3585245B2/ja not_active Expired - Fee Related
- 1998-06-16 ID IDW991697A patent/ID24673A/id unknown
- 1998-06-16 DE DE69820608T patent/DE69820608T2/de not_active Expired - Fee Related
- 1998-06-19 PA PA19988454001A patent/PA8454001A1/es unknown
- 1998-06-25 TW TW087110254A patent/TW382597B/zh not_active IP Right Cessation
- 1998-06-25 AP APAP/P/1998/001279A patent/AP945A/en active
- 1998-06-26 PE PE1998000575A patent/PE97299A1/es not_active Application Discontinuation
- 1998-06-29 GT GT199800090A patent/GT199800090A/es unknown
- 1998-06-29 AR ARP980103145A patent/AR015916A1/es not_active Application Discontinuation
- 1998-06-29 MY MYPI98002949A patent/MY119728A/en unknown
- 1998-06-29 UY UY25070A patent/UY25070A1/es not_active IP Right Cessation
- 1998-06-30 ZA ZA9805709A patent/ZA985709B/xx unknown
- 1998-06-30 MA MA25145A patent/MA24586A1/fr unknown
- 1998-06-30 DZ DZ980154A patent/DZ2544A1/fr active
- 1998-06-30 TN TNTNSN98123A patent/TNSN98123A1/fr unknown
- 1998-07-01 CO CO98037136A patent/CO4940405A1/es unknown
- 1998-07-01 HR HR980378A patent/HRP980378B1/xx not_active IP Right Cessation
-
1999
- 1999-11-23 BG BG103917A patent/BG103917A/bg unknown
- 1999-11-23 IS IS5266A patent/IS5266A/is unknown
- 1999-12-23 OA OA9900306A patent/OA11246A/en unknown
- 1999-12-27 NO NO996492A patent/NO996492L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN98112A1 (fr) | Composes dipeptidiques | |
| TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
| MA25284A1 (fr) | Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose. | |
| BR9713400A (pt) | Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese. | |
| TNSN98150A1 (fr) | Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN01017A1 (fr) | Compositions comprenant un antibiotique azalide, et procedes pour leur preparation | |
| TNSN98036A1 (fr) | Derives d'acide hexanoique nouveaux | |
| TNSN99053A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant | |
| TNSN00036A1 (fr) | Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN99110A1 (fr) | Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99186A1 (fr) | Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques | |
| TNSN98019A1 (fr) | Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN98194A1 (fr) | Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| EP1039935A4 (fr) | UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES | |
| TNSN99156A1 (fr) | Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26586A1 (fr) | Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant | |
| TNSN00231A1 (fr) | Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant | |
| TNSN98123A1 (fr) | Formes posologiques de sertraline et procede pour leur preparation | |
| TNSN98024A1 (fr) | 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2702148B1 (fr) | Application d'anticonvulsivants dans le traitement du neuro-sida. | |
| TNSN99198A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT | |
| TNSN01115A1 (fr) | Composition en particules contenant de l'eletriptan, et procede pour sa production | |
| FR2497510B1 (fr) | Composition pharmaceutique contenant de la g-butyrobetaine pour le traitement des syndromes provoques par une carence en l-carnitine |